# Lonza AG - Inspection Records Source: https://www.keypedia.com/companies/lonza-ag/7084f7e6-ce36-429f-942a-28e759416e70 > Inspection records and compliance data for Lonza AG in Visp, None. Access full analysis and detailed observations. --- ## Details - Name: Lonza AG - FEI Number: 3002930340 - City: Visp - State: None - Country Name: Switzerland - Address Line 1: Lonzastrasse 2 - Zip Code: None - Business Operations: API MANUFACTURE, API/FDF ANALYTICAL TESTING ## Related Documents - [483 - Lonza AG - 2025-10-28](https://www.keypedia.com/records/483/lonza-ag/f4d9edf5-cebe-4ccb-ade5-68cb73405681) — source: FDA, date: October 28, 2025 - [483 - Lonza AG - 2025-10-28](https://www.keypedia.com/records/483/lonza-ag/65951ebb-e28b-4ed1-9e9b-61dbae635dd6) — source: FDA, date: October 28, 2025 - [FDA Inspection 1303682 - Lonza AG - 2025-10-28](https://www.keypedia.com/records/fda_inspections/lonza-ag/78fcfce7-3d24-4ce5-9b7b-b09a46e71fee) — source: FDA, date: October 28, 2025 - [FDA Inspection 1279014 - Lonza AG - 2025-04-04](https://www.keypedia.com/records/fda_inspections/lonza-ag/c8382a61-bc25-45cc-bf72-f8219f1cd14b) — source: FDA, date: April 4, 2025 - [483 - Lonza AG - 2023-03-28](https://www.keypedia.com/records/483/lonza-ag/f928f76e-a480-4048-ae0c-9c4dc56c8947) — source: FDA, date: March 28, 2023 - [EIR - Lonza AG - 2023-03-28](https://www.keypedia.com/records/eir/lonza-ag/6ebda501-7241-4d95-8fe7-a77f9ba19386) — source: FDA, date: March 28, 2023 - [483 - Lonza AG - 2023-03-28](https://www.keypedia.com/records/483/lonza-ag/8b543d73-8cd2-405b-8095-49e641ba5fb2) — source: FDA, date: March 28, 2023 - [FDA Inspection 1204183 - Lonza AG - 2023-03-28](https://www.keypedia.com/records/fda_inspections/lonza-ag/87c8c9aa-762b-4daa-a90c-57b1f749b6c0) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 28, 2023 - [483 - Lonza AG - 2019-03-29](https://www.keypedia.com/records/483/lonza-ag/d2b94531-82a9-47ee-8dfc-06a69d21c1c6) — source: FDA, date: March 29, 2019 - [483 - Lonza AG - 2017-12-15](https://www.keypedia.com/records/483/lonza-ag/8a04ca07-4b1d-4652-b808-fa39c435dba7) — source: FDA, date: December 15, 2017 - [FDA Inspection 1035618 - Lonza AG - 2017-12-15](https://www.keypedia.com/records/fda_inspections/lonza-ag/6aabdbe9-cb78-4447-878b-509514b56a44) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 15, 2017 - [FDA Inspection 967811 - Lonza AG - 2016-03-11](https://www.keypedia.com/records/fda_inspections/lonza-ag/d3cf442a-abb3-4302-8fda-dc73abdabba3) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 11, 2016 - [FDA Inspection 893677 - Lonza AG - 2014-08-29](https://www.keypedia.com/records/fda_inspections/lonza-ag/f16885c5-b179-45f7-b826-f1969e2e6fa9) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 29, 2014 - [FDA Inspection 877791 - Lonza AG - 2014-04-02](https://www.keypedia.com/records/fda_inspections/lonza-ag/91715345-5bf7-4e52-ab96-660ea026d8e4) — classification: No Action Indicated (NAI), source: FDA, date: April 2, 2014 - [FDA Inspection 877791 - Lonza AG - 2014-04-02](https://www.keypedia.com/records/fda_inspections/lonza-ag/0b34a418-99bd-43d6-aff6-9dc35a24a434) — classification: No Action Indicated (NAI), source: FDA, date: April 2, 2014 - [FDA Inspection 826508 - Lonza AG - 2013-04-12](https://www.keypedia.com/records/fda_inspections/lonza-ag/e7f7ad5d-231a-4966-8821-f6d489c27d3c) — classification: No Action Indicated (NAI), source: FDA, date: April 12, 2013 - [FDA Inspection 818560 - Lonza AG - 2012-09-18](https://www.keypedia.com/records/fda_inspections/lonza-ag/0bbb540e-edb5-4c8d-ae18-5c3d4de9a3cb) — classification: No Action Indicated (NAI), source: FDA, date: September 18, 2012 ## Related Companies - [Biogen MA Inc.](https://www.keypedia.com/companies/biogen-ma-inc/85b778d2-1e69-485d-9e93-05c656646fa2) - [GlaxoSmithKline dba Human Genome Sciences Inc](https://www.keypedia.com/companies/glaxosmithkline-dba-human-genome-sciences-inc/c3dd2e54-125d-4d56-b0dc-18cb333074cc) - [Bachem Americas, Inc.](https://www.keypedia.com/companies/bachem-americas-inc/f0157d2d-6b0c-4b13-afd4-551c2ab94aad) - [Solara Active Pharma Sciences Limited](https://www.keypedia.com/companies/solara-active-pharma-sciences-limited/8f3f8236-f49d-43e3-84af-2cb404fb8264) - [Spark Therapeutics, Inc.](https://www.keypedia.com/companies/spark-therapeutics-inc/a5518493-a117-41d3-862d-96d5a5d3b6dd) - [Organo Sintesis, S.A. De C.V.](https://www.keypedia.com/companies/organo-sintesis-sa-de-cv/0d8f4d8d-0fbd-4c4a-8362-439c74e4f37d) - [UQUIFA Mexico, S.A. de C.V.](https://www.keypedia.com/companies/uquifa-mexico-sa-de-cv/8523a240-e52a-495e-a781-e12c6412dc69) - [AGILENT TECHNOLOGIES INC./US](https://www.keypedia.com/companies/agilent-technologies-incus/f39880d4-233e-44bc-9a9e-56d1f9b48065) - [MSN Laboratories Private Limited, Unit-II](https://www.keypedia.com/companies/msn-laboratories-private-limited-unit-ii/539d7af5-94e6-4abe-b01b-fa911be84d2a) - [SpecGx LLC](https://www.keypedia.com/companies/specgx-llc/715bb75a-8d3a-4469-9e6d-f617c2f39c93) ## Related Officers - [Maria J. Lopez-Barragan](https://www.keypedia.com/people/maria-j-lopez-barragan/ff280946-0ba6-4416-89a2-4cda19d18dea) - [Frances Namuswe](https://www.keypedia.com/people/frances-namuswe/d64cc7a2-3840-41c9-ae6c-fe225a651369) - [Ralph M. Bernstein](https://www.keypedia.com/people/ralph-m-bernstein/72173dfb-24ae-42a1-af9e-1dc7da02ed87) - [Reyes Candau-Chacón, Ph.D.](https://www.keypedia.com/people/reyes-candau-chacon-phd/c4e9fd50-2a2b-41a7-9cd0-db29dbb9171a) - [Vaishali J. Patel](https://www.keypedia.com/people/vaishali-j-patel/3d515b84-e0fd-4f96-914c-f7f09e2de307) - [Santos E. Camara](https://www.keypedia.com/people/santos-e-camara/18cea942-f6f9-4dec-9ce9-1c01c39009ce)